Search Insights

Insights

46 Insights found for Industries > Pharmaceuticals
TITLE
Event

A View from the Bench: The Federal Judges Speak on Paragraph IV Litigation

Paragraph IV Disputes Master Symposium – ACI’s Hatch-Waxman Series

Location:
Chicago, Ill.
Event

Obviousness at Another Glance: Exploring Secondary Considerations in ANDA Litigation

Paragraph IV Disputes Master Symposium – ACI’s Hatch-Waxman Series

Location:
Chicago, Ill.
Event
Event
News Release

Schiff Hardin Named One of 10 Firms “GCs Love for Pharma Work”

BTI’s Power Ranking 2016 recognized Schiff Hardin in its top category—Clientopia®—for the firm’s work on behalf of the pharmaceutical industry.

News Release

Clients Recognize Schiff Hardin as a Top Firm in Pharma Two Years in a Row

For the second consecutive year, Schiff Hardin has been recognized as a top “Clientopia” law firm in the BTI Industry Power Rankings 2017.

News Release

IP Practice Group Leader Recognized Among World’s Leading Patent Professionals

Schiff Hardin Intellectual Property Practice Group Co-Leader Imron Aly has been recognized as a leading patent litigator in Illinois in the 2017 IAM Patent 1000 guide, based on outstanding feedback from peers and clients.

News Release

Managing Intellectual Property Recommends Schiff Hardin, Highlights Three Attorneys

Schiff Hardin has been ranked “Highly Recommended” by Managing Intellectual Property magazine in the 2017 Illinois Patent Contentious category.

News Release

Schiff Hardin Adds White Collar Defense Lawyer William Ziegelmueller in Chicago

Ziegelmueller is an experienced trial lawyer who represents individual and corporate clients in federal criminal investigations, regulatory enforcement actions, civil litigation, and corporate internal investigations.

News Release

Schiff Hardin Expands Global Generic Pharmaceuticals Practice With Addition of Kevin M. Nelson in Chicago

Schiff Hardin LLP today announced the addition of Kevin M. Nelson as a partner in its rapidly growing Intellectual Property Group.

In The News
In The News
In The News
In The News
In The News
In The News

Patel Featured on BPCIA Litigation to Watch

The Center for Biosimilars

News Release

Schiff Hardin Advises on Public Offerings in Pharma, Tech Sectors

In the last 60 days, Schiff Hardin advised on the initial public offerings (IPO) for two companies and a public offering for another company, two in pharmaceuticals and one in the tech sector.

News Release

Schiff Hardin Named “Innovation Builder” by BTI

Schiff Hardin LLP has been singled out by corporate counsel as one of only 28 percent of law firms clients view as a BTI “Innovation Builder,” which recognizes firms that bring change to the legal market through new technology, services, strategies, or structures.

News Release

Schiff Hardin Recognized Among Managing Intellectual Property IP Stars

Schiff Hardin has been ranked as ‘Recommended’ by Managing Intellectual Property magazine in the Illinois IP Stars Patent Contentious category.

News Release

Schiff Hardin Secures Patent Infringement Win

Schiff Hardin successfully secured a favorable outcome for our client, Fresenius Kabi USA LLC, in a patent-infringement suit filed by Hospira Inc., which paves the way for Fresenius to market a new generic drug.

In The News
In The News
News Release

George Yu Named to Law360 2019 Life Sciences Advisory Board

Partner George Yu has been selected for the Law360 2019 Life Sciences Editorial Advisory Board. According to Law360, the purpose of the nine-lawyer board is to gain insight from experts in the field on how best to shape future coverage.

In The News
Alert

Pharma team scores rare preliminary injunction

Schiff Hardin’s pharma and life sciences patent litigation team, lead by partner Imron T. Aly, recently secured a preliminary injunction in federal court.

Alert

Pharma Giants in Antitrust Pricing Lawsuit over Biosimilars

Pfizer sued Johnson & Johnson (J&J) in federal court in Pennsylvania last week, alleging anticompetitive discounts and other actions to prevent competition with J&J’s biologic Remicade.

Alert

Supreme Court Delivers Big Patent-Dance-Limiting Win for Biosimilars

Earlier this week, the U.S. Supreme Court unanimously held, in its first case interpreting the Biologics Price Competition and Innovation Act of 2009, Sandoz Inc. v. Amgen Inc.

Blog Post

Who Won? The Verdict in the AndroGel Trial

Schiff Hardin Product Liability & Mass Torts Blog

Alert

Four Key Issues to Watch in the U.S. Biosimilars Industry

Like generic drugs in the 1980s, biosimilars today face a number of regulatory, legal, scientific, and public perception obstacles to continued growth.

Article
Article
Alert

How Pharmaceutical Companies Can Navigate FDA During Shutdown

As the government shutdown stretches on, pharmaceutical companies must manage the partial shutdown of the U.S. Food and Drug Administration (FDA).